Abstract Details

Title Epidemiology of the Reversible Cytotoxic Edema of the Splenium of the Corpus Callosum: A Midwest Tertiary Center Experience

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P03 - (-)

Poster/Presentation
Number 198

Objective

Background BACKGROUND: During the past decade multiple authors have reported cases of reversible CESCC without an associated clinical significance. However, the pathogenesis of CESCC is not fully understood. A recent review of the literature associates this entity with seizures and antiepileptic drugs, viral and bacterial infections, metabolic derangement, and toxins. The association between demographic and clinical presentation of CESCC is yet to be determined.

Design/Methods DESIGN/METHODS: This was a retrospective cohort study of MRIs performed at the University of Kansas Medical Center (KUMC) between 2000 and 2012. MRIs reports were identified by searching different keyword combinations including "corpus callosum", "stroke", "cytotoxic", and "splenium", using the KUMC Department of Radiology software Illuminate. The corresponding MRIs were individually reviewed, and only cases of true CESCC were selected. Corresponding patients' charts were reviewed, and demographic data including age, sex, clinical presentation and reason for MRI study, were reviewed.

Results RESULTS: 18,418 MRIs of the brain were performed from 2000 to 2012. 450 MRI reports met search criteria. Only 7 MRIs demonstrated isolated CESCC. Prevalence of CESCC was found to be 0.038%, or 0.003% per year, with a male to female ratio of 4:3. The average age of presentation with CESCC is 41 ± 16 years, with a duration of 18.3 ± 14.3 days. Of the 7 patients identified, 6 presented with alteration in level of consciousness, and 5 reported to have an associated headache.

Conclusions CONCLUSIONS: The prevalence of CESCC in the adult patient population at KUMC is rare. It has no gender predilection. In adults, it occurs between 20 to 60 years of age, typically presenting with alteration in mental status and associated headache. The lesions may last 1 to 4 weeks before completely resolving.

Authors/Disclosures
Hassanain Toma, MD (Royal Columbian Hospital) PRESENTER	No disclosure on file
Bradley F. Boeve, MD, FAAN (Mayo Clinic)	Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Gary S. Gronseth, MD, FAAN (University of Kansas)	Dr. Gronseth has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Brain & Life. Dr. Gronseth has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Gronseth has received personal compensation in the range of $0-$499 for serving as a Member/EBM consultant Guideline Development Subcommittee with AAN.

��ɫ��

��ɫ��